Lilly’s $3B Dutch Bet on Oral GLP-1 Manufacturing Revolution
Eli Lilly’s massive $3B investment in the Netherlands represents a strategic bet on next-generation oral drug manufacturing. The facility will pioneer advanced technologies to overcome bioavailability challenges in small molecule medications.










































